Market Cap 39.37B
Revenue (ttm) 9.91B
Net Income (ttm) 1.02B
EPS (ttm) N/A
PE Ratio 26.43
Forward PE 25.85
Profit Margin 10.27%
Debt to Equity Ratio 0.21
Volume 2,698,100
Avg Vol 1,909,800
Day's Range N/A - N/A
Shares Out 493.24M
Stochastic %K 14%
Beta 0.99
Analysts Strong Sell
Price Target $98.70

Company Profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 41 589 112 110
Address:
Chemin de Blandonnet 8, Vernier, Geneva, Switzerland
Jim1Winston
Jim1Winston Aug. 22 at 8:13 AM
$ALC How much will the stock price go up when the US tariff on Swiss products is reduced by 39% to 15..20%
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 6:27 PM
Wells Fargo has adjusted their stance on Alcon ( $ALC ), setting the rating to Equal-Weight with a target price of 93 → 88.
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 3:51 PM
Morgan Stanley has adjusted their stance on Alcon ( $ALC ), setting the rating to Equal-Weight with a target price of 84 → 80.
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 3:42 PM
Baird updates rating for Alcon ( $ALC ) to Outperform, target set at 108 → 95.
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 2:26 PM
$ALC misses revenue estimates while reporting a core EPS beat — what’s going on? 🤔 Second-quarter core EPS of 76 cents topped the Zacks Consensus by 7.04%, but net sales of $2.58B fell short by 1.29%. The stock dropped 10.1% post-announcement, highlighting market concerns. 📉 Understand the full picture here 👉 https://www.zacks.com/stock/news/2740887/alcons-q2-earnings-beat-estimates-revenues-miss-stock-plunges?cid=sm-stocktwits-2-2740887-body-8800&ADID=SYND_STOCKTWITS_TWEET_2_2740887_BODY_8800
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 1:26 PM
$ALC crushed EPS but the stock tanked 📉 Q2 earnings came in above estimates, but revenues missed — and the market punished it hard. Full breakdown here 👉 https://www.zacks.com/stock/news/2740887/alcons-q2-earnings-beat-estimates-revenues-miss-stock-plunges?cid=sm-stocktwits-2-2740887-teaser-8780&ADID=SYND_STOCKTWITS_TWEET_2_2740887_TEASER_8780
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 1:00 PM
JP Morgan has adjusted their stance on Alcon ( $ALC ), setting the rating to Neutral with a target price of 105.88 → 77.53.
0 · Reply
DipHunter23
DipHunter23 Aug. 21 at 12:11 PM
$ALC Alcon Inc. is a global leader in eye care, specializing in surgical equipment and vision care (contact lenses, solutions). It has a durable competitive moat and steady growth profile driven by an aging global population. A high-quality defensive healthcare stock.
0 · Reply
DayTradingPredictions
DayTradingPredictions Aug. 20 at 3:26 PM
$ALC ALC
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 20 at 12:46 PM
$ALC (-11.1% pre) Alcon reports second quarter sales rise 4% to $2.6 billion, acquires STAAR Surgical https://ooc.bz/l/74591
0 · Reply
Latest News on ALC
Alcon to Present at 2025 Baird Global Healthcare Conference

Aug 26, 2025, 8:00 AM EDT - 7 days ago

Alcon to Present at 2025 Baird Global Healthcare Conference


Trouble Ahead for Alcon Shares

Aug 22, 2025, 10:28 AM EDT - 11 days ago

Trouble Ahead for Alcon Shares


These Analysts Slash Their Forecasts On Alcon After Q2 Earnings

Aug 21, 2025, 8:48 AM EDT - 12 days ago

These Analysts Slash Their Forecasts On Alcon After Q2 Earnings


Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript

Aug 20, 2025, 9:10 PM EDT - 12 days ago

Alcon Inc. (ALC) Q2 2025 Earnings Call Transcript


Alcon: More Than Meets The Eye

Aug 20, 2025, 11:33 AM EDT - 13 days ago

Alcon: More Than Meets The Eye


Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit

Aug 20, 2025, 5:03 AM EDT - 13 days ago

Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit


Alcon Agrees to Acquire STAAR Surgical

Aug 5, 2025, 1:01 AM EDT - 4 weeks ago

Alcon Agrees to Acquire STAAR Surgical

STAA


Alcon Canada Earns Global Recognition as a Top Employer

Jun 26, 2025, 9:03 AM EDT - 2 months ago

Alcon Canada Earns Global Recognition as a Top Employer


US FDA approves Alcon's new dry-eye drug

May 28, 2025, 5:47 PM EDT - 3 months ago

US FDA approves Alcon's new dry-eye drug


Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:03 PM EDT - 3 months ago

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript


Alcon Announces Results of 2025 Annual General Meeting

May 6, 2025, 4:30 PM EDT - 4 months ago

Alcon Announces Results of 2025 Annual General Meeting


Alcon Publishes Agenda for 2025 Annual General Meeting

Apr 4, 2025, 1:00 AM EDT - 5 months ago

Alcon Publishes Agenda for 2025 Annual General Meeting


Alcon Agrees to Acquire LENSAR, Inc.

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Alcon Agrees to Acquire LENSAR, Inc.


Alcon to Host 2025 Capital Markets Day

Mar 13, 2025, 9:02 AM EDT - 6 months ago

Alcon to Host 2025 Capital Markets Day


Watch CNBC's full interview with Alcon CEO David Endicott

Feb 26, 2025, 8:54 PM EST - 6 months ago

Watch CNBC's full interview with Alcon CEO David Endicott


Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:51 AM EST - 6 months ago

Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript


Alcon eyes revenue growth in 2025 after in-line results

Feb 26, 2025, 2:13 AM EST - 6 months ago

Alcon eyes revenue growth in 2025 after in-line results


Alcon: Q3, Slight Guidance Cut Is Not Something Structural

Nov 14, 2024, 12:17 AM EST - 10 months ago

Alcon: Q3, Slight Guidance Cut Is Not Something Structural


Alcon (ALC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:24 PM EST - 10 months ago

Alcon (ALC) Q3 2024 Earnings Call Transcript


Alcon cuts 2024 forecasts, as slow US hits surgical unit

Nov 13, 2024, 2:17 AM EST - 10 months ago

Alcon cuts 2024 forecasts, as slow US hits surgical unit


Alcon Analysts Increase Their Forecasts After Q2 Results

Aug 22, 2024, 12:00 PM EDT - 1 year ago

Alcon Analysts Increase Their Forecasts After Q2 Results


Alcon CEO: 'Very good' revenue and underlying demand in Q2

Aug 22, 2024, 10:54 AM EDT - 1 year ago

Alcon CEO: 'Very good' revenue and underlying demand in Q2


Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript

Aug 21, 2024, 12:05 PM EDT - 1 year ago

Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript


Jim1Winston
Jim1Winston Aug. 22 at 8:13 AM
$ALC How much will the stock price go up when the US tariff on Swiss products is reduced by 39% to 15..20%
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 6:27 PM
Wells Fargo has adjusted their stance on Alcon ( $ALC ), setting the rating to Equal-Weight with a target price of 93 → 88.
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 3:51 PM
Morgan Stanley has adjusted their stance on Alcon ( $ALC ), setting the rating to Equal-Weight with a target price of 84 → 80.
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 3:42 PM
Baird updates rating for Alcon ( $ALC ) to Outperform, target set at 108 → 95.
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 2:26 PM
$ALC misses revenue estimates while reporting a core EPS beat — what’s going on? 🤔 Second-quarter core EPS of 76 cents topped the Zacks Consensus by 7.04%, but net sales of $2.58B fell short by 1.29%. The stock dropped 10.1% post-announcement, highlighting market concerns. 📉 Understand the full picture here 👉 https://www.zacks.com/stock/news/2740887/alcons-q2-earnings-beat-estimates-revenues-miss-stock-plunges?cid=sm-stocktwits-2-2740887-body-8800&ADID=SYND_STOCKTWITS_TWEET_2_2740887_BODY_8800
0 · Reply
ZacksResearch
ZacksResearch Aug. 21 at 1:26 PM
$ALC crushed EPS but the stock tanked 📉 Q2 earnings came in above estimates, but revenues missed — and the market punished it hard. Full breakdown here 👉 https://www.zacks.com/stock/news/2740887/alcons-q2-earnings-beat-estimates-revenues-miss-stock-plunges?cid=sm-stocktwits-2-2740887-teaser-8780&ADID=SYND_STOCKTWITS_TWEET_2_2740887_TEASER_8780
0 · Reply
JarvisFlow
JarvisFlow Aug. 21 at 1:00 PM
JP Morgan has adjusted their stance on Alcon ( $ALC ), setting the rating to Neutral with a target price of 105.88 → 77.53.
0 · Reply
DipHunter23
DipHunter23 Aug. 21 at 12:11 PM
$ALC Alcon Inc. is a global leader in eye care, specializing in surgical equipment and vision care (contact lenses, solutions). It has a durable competitive moat and steady growth profile driven by an aging global population. A high-quality defensive healthcare stock.
0 · Reply
DayTradingPredictions
DayTradingPredictions Aug. 20 at 3:26 PM
$ALC ALC
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 20 at 12:46 PM
$ALC (-11.1% pre) Alcon reports second quarter sales rise 4% to $2.6 billion, acquires STAAR Surgical https://ooc.bz/l/74591
0 · Reply
BPharmCatalyst
BPharmCatalyst Aug. 20 at 12:12 PM
$NVNO received an FDA not-approvable letter for its VenoValve PMA, citing insufficient evidence of benefit-risk despite improvements in clinical scores and raising safety concerns tied to the surgical procedure. The company is evaluating options, including a potential resubmission or appeal, while shifting its focus toward its non-surgical enVVe valve. $CLDX $CTSO $RCKT $ALC See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/enveno-nvno-not-approvable-letter-celldex-cldx-phase-2-data
0 · Reply
anachartanalyst
anachartanalyst Aug. 20 at 11:01 AM
$ALC https://anachart.com/wp-content/uploads/ana_temp/1755687684_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Aug. 20 at 10:30 AM
Needham has adjusted their stance on Alcon ( $ALC ), setting the rating to Buy with a target price of 107.
1 · Reply
Estimize
Estimize Aug. 19 at 9:24 PM
$ALC reported 0.76 EPS and 2,577 revenue for Q2. http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_content=ALC&utm_med
0 · Reply
yousef112
yousef112 Aug. 19 at 8:45 PM
$ALC 84.60$
0 · Reply
DonCorleone77
DonCorleone77 Aug. 19 at 8:41 PM
$ALC Alcon reports Q2 EPS 76c, consensus 72c -- Q2 revenue $2.58B, consensus $2.64B. -- Affirms FY25 EPS view $3.05-$3.15, consensus $3.12 -- Cuts FY25 revenue view to $10.3B-$10.4B from $10.4B-$10.5B, consensus $10.49B. -- Lowers FY25 operating margin view to 19.5%-20.5% from 20%-21%.
0 · Reply
ChessGM
ChessGM Aug. 19 at 11:26 AM
$ALC "Heads up alert! Only one day until Upcoming earnings on Wednesday, 8/20/2025 for $ALC Bullish (8.2) --- Alcon (NYSE: ALC) has recently been in the spotlight due to its strategic acquisition activities and expansion in the ophthalmology sector. The company's acquisition of STAAR Surgical for $1.5 billion is a significant move that positions Alcon to expand its portfolio in vision correction, particularly with the inclusion of STAAR's EVO family of lenses for myopia and astigmatism. This acquisition is expected to enhance Alcon's market share and competitive edge in the high-growth vision correction segment. Financially, Alcon has demonstrated robust performance with a positive outlook. The P/E ratio remains competitive within the industry, suggesting that the stock is reasonably valued compared to peers. The company's EPS growth is noteworthy, indicating strong operational efficiency and profitability. Revenue forecasts are optimistic, bolstered by strategic acquisitions and innovative product offerings, such as the UNITY VCS technology recently approved in Canada, which enhances surgical precision. Compared to industry peers like Carl Zeiss and Johnson & Johnson, Alcon's focus on strategic acquisitions and product innovation sets it apart as a leader in the ophthalmology market. --- The upcoming earnings report for Alcon is anticipated with considerable interest, especially following recent strategic developments. Historically, Alcon has shown consistent performance in its quarterly earnings, often meeting or exceeding analyst expectations. For the current period, analysts have been revising their estimates upwards, reflecting confidence in Alcon's growth trajectory post-acquisition of STAAR Surgical. The market expects Alcon to report strong earnings growth, driven by the integration of STAAR's product line and the anticipated synergies from the acquisition. Historically, such strategic moves have positively impacted Alcon's stock, and a strong earnings report could further bolster investor confidence, potentially leading to an uptick in stock price. --- The healthcare sector, particularly the ophthalmology segment, has been experiencing mixed performance. While some companies face challenges due to reimbursement issues and regulatory hurdles, others like Alcon have managed to navigate these challenges through strategic acquisitions and innovation. The overall sector remains resilient, with a moderate growth outlook, driven by demographic trends such as an aging population and increased demand for vision correction solutions. The sector's performance is expected to remain stable, with pockets of growth opportunities for companies that can effectively leverage technological advancements and strategic partnerships. - Funds were net buyers of $ALC during the previous reporting quarter. - Funds with large holdings in $ALC include: - Aristotle Capital Management LLC, MV: $1,063MM. Fund Rank: 73% www.aristotlecap.com - AKO Capital LLP, MV: $681MM. Fund Rank: 84% www.akocapital.com - Select Equity Group LP, MV: $596MM. Fund Rank: 70% www.selectequity.com - Cantillon Captal Management LLC, MV: $252MM. Fund Rank: 73% www.cantillon.com - King Luther Cap, MV: $188MM. Fund Rank: 63% - Last 10 days performance: 3% - Last 30 days performance: 1% - Last 90 days performance: 1% Some of the latest news articles: - Title: Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS Publication Date: 8/19/2025 3:00:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/alcon-underscores-benefits-iols-cataract-030000073.html?.tsrc=rss - Title: Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics Publication Date: 8/14/2025 1:15:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/stay-ahead-game-alcon-alc-131502485.html?.tsrc=rss - Title: Takeover Agreement with Alcon Sparks Sharp Weekly Gains for STAAR Surgical Publication Date: 8/13/2025 5:17:35 AM, Source: yahoo URL: https://finance.yahoo.com/news/takeover-agreement-alcon-sparks-sharp-051735915.html?.tsrc=rss - Title: This Restored 1999 Defender 110 with an LT1 and French Oak Evokes ‘Old English’ Publication Date: 8/12/2025 12:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/restored-1999-defender-110-lt1-120500153.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
Estimize
Estimize Aug. 14 at 8:00 PM
Wall St is expecting 0.80 EPS for $ALC Q3 [Reporting 11/12 AMC] http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 10:30 AM
Needham has adjusted their stance on Alcon ( $ALC ), setting the rating to Buy with a target price of 107.
0 · Reply
JarvisFlow
JarvisFlow Aug. 8 at 10:00 AM
Wells Fargo updates rating for Alcon ( $ALC ) to Equal-Weight, target set at 93.
0 · Reply
BPharmCatalyst
BPharmCatalyst Aug. 5 at 7:23 PM
Pre-Market Updates 08/05/25 $STAA will be acquired by $ALC for $1.5 billion, or $28 per share, representing a 51% premium over its closin
0 · Reply
DonCorleone77
DonCorleone77 Aug. 5 at 9:26 AM
$ALC $STAA Alcon to acquire Staar Surgical for $28 per share in cash
1 · Reply